Development of a pneumococcal conjugate vaccine based on chemical conjugation of polysaccharide serotype 6B to PspA

Full metadata record
DC FieldValueLanguage
dc.contributorCentro de Biotecnologia e Sanguept_BR
dc.contributorLab. Bacteriologiapt_BR
dc.contributor.authorSantiesteban-Lores, Lazara Elenapt_BR
dc.contributor.authorCabrera-Crespo, Joaquinpt_BR
dc.contributor.authorCarvalho, Eneaspt_BR
dc.identifier.citationSantiesteban-Lores LE, Cabrera-Crespo J, Carvalho E. Development of a pneumococcal conjugate vaccine based on chemical conjugation of polysaccharide serotype 6B to PspA. Microb. Pathog.. 2021 Sept;158:105092. doi:10.1016/j.micpath.2021.105092.pt_BR
dc.description.abstractThe use of conjugate vaccines remains an effective intervention to prevent pneumococcal diseases. In order to expand vaccine coverage, the inclusion of pneumococcal proteins as carriers is a propitious alternative that has been explored over the past few years. In this study, pneumococcal surface protein A (PspA) clade 1, family 1 (PspA1) and clade 3, family 2 (PspA3) were used as carrier proteins for pneumococcal capsular polysaccharide serotype 6B (Ps6B). Employing an improved reductive amination chemistry, 50% of Ps6B was incorporated to each protein, PspA1 and PspA3. The effect of chemical modifications in Ps6B and PspA was assessed by an antigenicity assay and circular dichroism, respectively. Fragmentation and oxidation decreased the antigenicity of Ps6B while conjugation improved antigenicity. In the same manner, introduction of adipic acid dihydrazide (ADH) reduced PspA secondary structure content, which was partially restored after conjugation. Immunization of Ps6B-PspA1 and Ps6B-PspA3 conjugates in mice induced specific IgG antibodies against the Ps6B and the protein; and anti-PspA antibodies had functional activity against two pneumococcal strains with different serotypes. These results suggest that chemical coupling between Ps6B and PspA did not affect antigenic epitopes and support the further development of PspA as a carrier protein in pneumococcal conjugate vaccines to provide broader protection.pt_BR
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)pt_BR
dc.relation.ispartofMicrobial Pathogenesispt_BR
dc.rightsAcesso restritopt_BR
dc.titleDevelopment of a pneumococcal conjugate vaccine based on chemical conjugation of polysaccharide serotype 6B to PspApt_BR
dc.contributor.externalUniversidade de São Paulo (USP)pt_BR
dc.subject.keywordPneumococcal conjugate vaccinespt_BR
dc.subject.keywordPneumococcal serotype 6Bpt_BR
dc.subject.keywordReductive aminationpt_BR
dc.relation.ispartofabbreviatedMicrob. Pathog.pt_BR
dc.identifier.citationabntv. 158, 105092, set. 2021pt_BR
dc.identifier.citationvancouver2021 Sept;158:105092pt_BR
dc.contributor.butantanSantiesteban-Lores, Lazara Elena|:Desvinculado|:Centro de Biotecnologia e Sangue|:PrimeiroAutorpt_BR
dc.contributor.butantanCabrera-Crespo, Joaquin|:Pesquisador|:Centro de Biotecnologia e Sanguept_BR
dc.contributor.butantanCarvalho, Eneas|:Pesquisador|:Centro de Biotecnologia e Sanguept_BR
dc.sponsorship.butantanConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)¦¦190519/2013-4pt_BR
item.fulltextCom Texto completo-
Appears in Collections:Artigos de periódicos

Files in This Item:

Existing users please Login
Size: 1.02 MB
Format: Adobe PDF
Embargoed until January 1, 2999    Request a copy
Show simple item record

The access to the publications deposited in this repository respects the licenses from journals and publishers.